Previous 10 | Next 10 |
Anchiano Therapeutics (NASDAQ: ANCN ): Q3 GAAP EPS of -$0.43 misses by $0.25 . cash and cash equivalents of $23.2M. Press Release More news on: Anchiano Therapeutics Ltd, Earnings news and commentary, Healthcare stocks news, ,
CAMBRIDGE, Mass., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a biopharmaceutical company focused on discovery and development of novel therapies to treat cancer, today reported financial results for its third quarter and nine mont...
CAMBRIDGE, Mass., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano” or the “Company”), a biopharmaceutical company focused on discovery and development of targeted therapies to treat cancer, today announced the discontinuatio...
CAMBRIDGE, Mass., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano” or the “Company”), a pivotal-stage biopharmaceutical company focused on the discovery and development of targeted therapies to treat cancer, today announced ...
Anchiano will make an upfront payment in exchange for the option to in-license at any time through obtaining an Investigational New Drug (IND) designation Company also provides update on accrual to its ongoing pivotal Phase 2 Codex trial Anchiano to hold a call on Tuesday, Septem...
CAMBRIDGE, Mass., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced that Frank Haluska, M.D., Ph.D., ...
CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced that Frank Haluska, M.D., Ph.D., ...
Anchiano Therapeutics (NASDAQ: ANCN ): Q2 GAAP EPS of -$0.05 beats by $0.12 . More news on: Anchiano Therapeutics Ltd, Earnings news and commentary, Healthcare stocks news, , Read more ...
CAMBRIDGE, Mass., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today reported financial results for its second qu...
CAMBRIDGE, Mass., June 18, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced that it completed the process to v...
News, Short Squeeze, Breakout and More Instantly...
Anchiano s hareholders approve all resolutions at shareholder meeting The merged company is expected to receive approximate gross proceeds from the private financing of $ 45 .5 million, which will be used to a dvance the Chemomab...
Are These 5 Biotech Penny Stocks Worth Watching? With the extraordinary times we live in, Covid has resulted in a large investor focus on biotech penny stocks. Within the stock market, there’s no shortage of interesting biotech companies to choose from. In 2021, it’s best ...
NEW YORK, NY / ACCESSWIRE / February 3, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in N...